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IN VIVO ANALYSIS OF CCM3, A GENE INVOLVED IN CEREBRAL 
CAVERNOUS MALFORMATION DEVELOPMENT.   
 
Aimee Two, Angeliki Louvi, and Murat Gunel.  Department of Neurosurgery, Yale 
University, School of Medicine, New Haven, CT. 
 
Cerebral cavernous malformations (CCMs), one of the most common vascular 
malformations of the central nervous system (CNS), occur due to both sporadic and 
familial mutations in any of the three CCM genes: CCM1, or KRIT1; CCM2, or 
malcavernin; and CCM3, the Programmed Cell Death 10 gene.  As the most recently 
discovered of these genes, CCM3 remains poorly understood.  In vitro analysis has 
suggested a role for it in apoptosis, but in vivo studies of this gene are limited and thus 
are the goal of the current work. Using conditional knockout mice in which Ccm3 has 
been inactivated in neural cells, experimental animals were created that develop lesions 
resembling human CCMs.  In situ hybridization and immunohistochemistry were used to 
compare staining patterns of glial fibrillary acidic protein (GFAP) and vimentin, both 
expressed in astrocytes, with vimentin being expressed specifically in activated 
astrocytes, as well as connexin43, a gap junction protein that links astrocytic foot 
processes along the blood brain barrier (BBB), and aquaporin 4, a water channel 
expressed exclusively in astrocytes, between control and experimental brains.  Results 
showed an increase in GFAP and vimentin expression in experimental brains, suggesting 
increased glial activation, but a decrease in that of connexin43 and aquaporin 4, 
suggesting an abnormality of these astrocytes.  Given that CCMs represent endothelial 
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cell and not astrocyte pathology, these results suggest that lesion formation may be 
related to disrupted communication within the neurovascular unit.  
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INTRODUCTION 
 
Cerebral cavernous malformations (CCMs), or cavernomas, are low-flow vascular lesions 
most commonly found in the central nervous system (CNS).  They consist of a compact 
mass of abnormally dilated vascular channels lacking intervening neural parenchyma.  
The vascular channels comprising these lesions resemble capillaries in that they consist 
of a single endothelial layer and lack structural elements such as elastin and smooth 
muscle normally found in the walls of other vessels.  Unlike capillaries, however, these 
vessels are “leaky,” allowing for frequent microhemorrhages that permit blood to escape 
into the surrounding brain tissue [1].  In addition to hemorrhaging, these lesions can 
thrombose, which also causes lesion expansion, and, if significant, can compress nearby 
brain structures.  When grossly examined, malformations are raspberry-like in 
appearance and range in diameter from one millimeter to several centimeters.  In addition 
to the CNS, these lesions can occasionally be seen in most other organ systems of the 
body, including the skin and eye. 
 
Before the advent of MRI, CCMs were thought to be rare lesions.  Radiographic 
techniques at that time failed to properly diagnose these malformations, and thus CCMs 
were only detected after surgical resection or during autopsies.  The first study to suggest 
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a higher than expected prevalence of CCMs was an autopsy-based report published in 
1989 suggesting a prevalence of 0.4% [2].  This finding was confirmed soon after by 
MRI-based studies that suggested the prevalence of CCMs to range from 0.4 to 0.9% [3, 
4].  Given these statistics, CCMs are now recognized as a relatively common vascular 
malformation afflicting one in approximately 200 individuals and comprising 8-15% of 
vascular malformations of the CNS [5, 6]. 
 
One of the main reasons the recognition of CCMs as a common vascular lesion required 
autopsy- and MRI-based studies is because of the disease’s clinical presentation.  Only 
20-30% of patients with CCMs experience lesion-related symptoms during their lifetime, 
and thus most never present to healthcare providers [3].  Those that do present for 
medical attention usually do so during their 3
rd
 to 5
th
 decade of life after experiencing 
such symptoms as headaches, seizures, and focal neurologic deficits [3].  Life-threatening 
intracerebral hemorrhages can also occur, but are extremely rare, occurring in 0.25% to 
6% of patients [7-9]. 
 
The onset of symptoms in patients with CCMs is always related to some change in the 
lesion itself.  Given the leakiness of the vascular channels comprising these lesions, 
microhemorrhages are common, and thus blood frequently extravasates from these 
lesions into the surrounding neural parenchyma, where it is metabolized over a period of 
days to weeks [10].  Blood break-down products accumulate in the surrounding brain 
tissue during this time and can serve as a focus for seizure activity.  Aside from these 
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long-term consequences, microhemorrhages are often clinically silent.  Their high 
frequency helps explains why seizures are the most common presenting symptom for 
CCMs [11, 12].   
 
The remainder of symptoms associated with cavernomas is attributable to lesion 
expansion.  Lesion expansion can occur through one of two means: gross hemorrhage or 
lesion thrombosis [10].  With a gross hemorrhage, a significant amount of blood escapes 
from the lesion at a rate that cannot be accommodated by the closed intracranial space.  
Similarly, when a thrombus forms within a lesion, the lesion becomes congested with 
blood and swells.  If the intracranial space cannot accommodate the swelling, symptoms 
ensue due to the resulting mass effect.  Additionally, the increased pressure seen 
upstream of a clot in a cavernoma can cause rupture of the lesion and thus gross 
hemorrhage [13].  Since cavernomas generally represent a low-pressure, low-flow state, 
though, large bleeds are relatively uncommon.  Although the annual rate of clinically 
significant hemorrhages can vary greatly among patients, it is generally thought to range 
from 2 to 5% [14].   
 
Another common presentation of CCMs is through incidental detection on imaging 
studies performed for unrelated reasons.  As previously discussed, the increasing use of 
MRI has allowed for detection of lesions that otherwise would have remained 
undiagnosed [3, 4].  Despite advances in CCM detection, however, treatment options for 
these potentially devastating lesions unfortunately remain limited.  Complete surgical 
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resection is the only true cure for CCMs, but this option is not available to all patients.  
Older patients or those with significant co-morbidities may not be appropriate candidates 
for undergoing the often extensive procedure of CCM removal.  In such cases, the risks 
of surgery outweigh its potential benefits, and thus an alternative treatment must be 
sought.  Similarly, the location and surgical accessibility of a lesion also must be 
considered when planning treatment.  CCMs in or near eloquent brain structures or in 
regions that cannot easily be reached surgically may not be amenable to resection.  
Finally, patients with the familial form of the disease may have upwards of hundreds of 
lesions, and thus surgery on all of them would be impossible. 
 
For patients in whom surgery is not an option, alternative management strategies are 
limited.  Medical management can be used for seizure control, but aside from alleviating 
this symptom, pharmacologic agents have no role in the treatment of cavernomas.  Even 
when anti-epileptic drugs are used, though, seizures are not always relieved.  Since the 
seizure focus in patients with CCMs is usually hemosiderin that has accumulated in the 
brain tissue surrounding lesions after repeated microhemorrhages, anti-epileptic drugs fail 
to eliminate the source of seizures in these patients.  These medications therefore merely 
increase the seizure threshold of the local tissue, which can be completely curative for 
some patients, but leaves others still to experience symptoms, at times even despite the 
use of multiple agents.  For these patients with refractory seizures causing significant 
impairment in a patient’s life, surgery would again be the recommended treatment option. 
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For patients not receiving either surgical or medical management, expectant management 
is the preferred option for managing CCMs.  This strategy is preferred for patients with 
lesions that are not surgically accessible, as well as for asymptomatic patients in whom 
the benefits of surgery may not outweigh the risks.  Under this management plan, patients 
are followed with serial MRIs every year or two, and new scans compared to older ones 
for any evidence of lesion enlargement or hemorrhage.  If the scan shows no new changes 
to the lesion, the patient can continue to be followed expectantly.  If changes are present, 
though, intervention may be necessary, which then leaves patients with surgery as their 
only option.   
 
Although radiosurgery has also been suggested as a treatment option for CCMs, most of 
the available literature on this topic fails to show a clear benefit of this procedure.  While 
some studies report decreased hemorrhage rates following radiosurgery [15, 16], others, 
including some of these same studies, show an increased complication rate following this 
treatment, including permanent neurological deficits [17-19].  Patients in one study also 
had to undergo surgical resection of their lesions after radiosurgery due to its inability to 
completely thrombose the cavernoma [18].  This finding prompted histological studies of 
lesions resected from patients who had previously undergone radiosurgical treatment of 
their cavernomas.  The specimens in these studies were not occluded, suggesting that 
radiosurgery fails to adequately treat these lesions [20].  For these reasons, the use of 
radiosurgery as a treatment for CCMs remains a topic of much controversy. 
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As the only truly curative option for CCM management, surgery is therefore the preferred 
treatment option for these lesions.  Such an intervention is not without risks, though, and 
these can range from permanent focal neurologic deficits to death.  Given the limited 
treatment options for CCMs as well as the potential risks of such an operation, it is clear 
why better treatment options for cavernomas must be sought.  In order to accomplish this 
goal, though, further understanding of the disease, including its underlying molecular 
mechanisms, is necessary.   
 
As a genetic condition, the heritable nature of cavernomas has been recognized since the 
disease’s original description, and this feature has played a large role in allowing for 
significant advances in elucidating the underlying molecular pathophysiology of these 
lesions [21].  Although sporadic mutations contribute to the majority of the disease’s 
prevalence, 10-50% of cavernomas are inherited [22, 23]. Familial CCMs are inherited in 
an autosomal dominant fashion with a high degree of penetrance, making it a relatively 
common genetic disorder in afflicted families.  Through genetic linkage analyses using 
afflicted families, three loci were discovered to play a role in the development of these 
lesions [24-28].  Subsequent positional cloning experiments identified the three genes 
that lie within those loci as CCM1, CCM2, and CCM3.  Together mutations in these three 
genes are thought to account for 96% of familial cavernomas [29]. 
 
CCM1, or Krev1 interaction trapped protein-1 (KRIT1), lies on chromosome 7q21 and 
contains 16 exons that encode the 736 amino acid protein KRIT1.  Over 80 different 
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mutations in this gene have been found that lead to clinically evident CCMs, including 
one that is responsible for over 90% of familial cases in Hispanic-American patients.  
Almost all of these mutations are nonsense mutations in which a premature stop codon or 
a frameshift mutation results in premature termination of translation [30-35], providing 
evidence that disease is caused by a loss-of-function mutation and suggesting a two-hit 
mechanism of disease development [36].  The first “hit” in this case would be an 
inherited germ line mutation, and the second “hit” acquired in affected cells. 
 
As the first of the CCM genes to be identified, CCM1’s function has been studied in great 
detail.  Its resulting protein, KRIT1, has been found to have several domains implicated 
in protein-protein interactions, including one, a FERM domain, that is typically critical 
for binding to the cell membrane [37].  It also contains a series of ankyrin repeats, whose 
interactions remain unknown, as well as 3 NPXY domains through which it is thought to 
associate with Integrin Cytoplasmic domain-Associated Protein-1α (ICAP-1α) [38, 39] 
and CCM2 [40].  ICAP1α is known to bind to β1 integrin [41, 42], and integrins, 
specifically β1 integrin, are important proteins that regulate endothelial cell adhesion and 
migration throughout angiogenesis [43, 44].  These findings therefore suggest a role for 
CCM1 in vascular development, a result that is confirmed by in vivo analysis. 
 
Interactions between CCM1 and CCM2 have also been studied extensively.  Results have 
shown that these two molecules bind not only to each other, but also to CCM3 [45, 46].  
Although the exact role of this complex is not known, CCM2 appears to play a 
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scaffolding role [47], potentially being recruited to cell-cell junctions through its 
interactions with CCM1. 
 
KRIT1 is expressed in many human tissues, but most relevant to CCM pathology is its 
presence in neurons, astrocytes, and the endothelium of arteries and capillaries [48].  
Consistent with this localization, in vivo studies suggest that CCM1 plays an essential 
role in vascular development.  Ccm1 knock-out mice are embryonically lethal due to 
vascular defects incompatible with life.  Post-mortem analysis of these embryos 
demonstrates an enlarged caudal dorsal aorta, dilated brain precursor vessels, and 
variable obstruction of branchial arch arteries and the proximal dorsal aorta  [49].  In 
contrast, Ccm1
+/- 
animals survive embryogenesis and are phenotypically normal. Crossing 
them with p53
-/- 
mutants, however, results in development of vascular lesions resembling 
cavernomas in about 55% of Ccm1
+/- 
p53
-/- 
animals [50].  Although the mechanism 
underlying the enhanced phenotype in the absence of p53 is not known, it is speculated to 
be due to increased rate of somatic mutations leading to more second hits and thereby 
resulting in the formation of CCM lesions in the compound animals.  Nonetheless, these 
findings once again implicate CCM1 in the development of these vascular lesions. 
 
The CCM2 gene is MGC4607, or malcavernin.  MGC4607 is a ten exon gene located on 
chromosome 7p13 and encoding the CCM2 protein.  Almost all CCM2 mutations in 
affected patients are nonsense mutations, resulting from premature stop codons or 
frameshift mutations that imply loss-of-function of CCM2 as the cause of the resulting 
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pathophysiology.  The expression pattern of CCM2 is similar to that of CCM1, localizing 
to neurons, astrocytes and the arterial endothelium.  Although its function is not 
completely known, CCM2 has significant homology to OSM, a protein in rodents that is 
responsible for osmo- and mechano-sensing of the extracellular matrix.  In humans, 
CCM2 plays a role as a scaffolding protein, using p38 signaling to convey information 
about environmental stress [47].  In addition, in vivo studies predict that CCM2 has a 
major angiogenic role since Ccm2 knock-out mice, like the Ccm1 mutants, die during 
embryogenesis due to gross vascular defects [49, 51]. 
 
Most recently, PDCD10, or Programmed Cell Death 10 was identified as being the 
causative gene in CCM3 families.  This seven exon gene is located on 3q26 and encodes 
a 212 amino acid protein.  Interestingly, CCM3 also shares the expression pattern of 
CCM1 and CCM2, being present in the arterial portion of the endothelium as well as 
neurons and astrocytes [52].  In vitro studies of CCM3 suggest that it is both necessary 
and sufficient to induce apoptosis [53].  However, being the most recently identified, the 
least is known about this gene.   
 
Gaining further insight to the CCM3 gene is critical for better understanding the 
pathophysiology underlying this disease.  Although the gene’s in vitro role in apoptosis 
has been clearly defined, its in vivo function remains to be elucidated.  Like Ccm1 and 
Ccm2 knock-out animals, Ccm3 complete knock-outs are embryonical lethal due to 
vascular defects (Y. He, H. Zhang, L. Yu, M. Günel and W. Min: PDCD10/CCM3 is 
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critical for vascular development by regulating VEGFR2-MEKK3-MAPK signaling, 
submitted).  Therefore, to further understand this gene’s role in vivo, cell-specific 
conditional Ccm3 knock-out mice were generated in whichCcm3 was selectively 
inactivated in specific cells of a particular lineage using different promoters to drive Cre 
recombinase.  Given that CCMs are vascular lesions, the first such conditional knock-
outs targeted the vascular system using Tie-2, a promoter specific to endothelial cells 
[54].  Animals with this mutation did not survive embryogenesis, though, as they died 
between embryonic days 9 and 10 of gross vascular defects.  The brain was the next 
organ system targeted since this is the location where lesions are most commonly seen, 
and two different promoters were used to selectively inactivate Ccm3 in different neural 
cell lines.  In one, glial fibrillary acidic protein (GFAP) was used to target radial glial 
cells, and in the other, Emx1 was used to target dorsal telencephalic progenitor cells.  
More specifically, GFAP is expressed in radial glial cells and their progeny, including 
neurons and astrocytes of both the cerebral and cerebellar cortices [55, 56], and Emx1 is 
expressed in telencephalic neuronal progenitors, including neurons of the neocortex and 
hippocampus as well as astrocytes and oligodendroglia [57].  Not only do animals in both 
of these experimental strains survived embryogenesis, but many, including most of the 
Emx1 animals, survived through the weaning process and into adulthood, allowing for 
characterization of these animals’ brains at various stages of postnatal development. 
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STATEMENT OF PURPOSE AND HYPOTHESIS 
 
The goal of this research is to examine the role of CCM3 in brain development and in the 
pathophysiology of CCMs using an animal model in which Ccm3 has been selectively 
inactivated in neural cells in the CNS of mice.  These mutant brains will be examined for 
gross morphology, cytoarchitecture and expression of cellular markers, and these results 
compared to those of control brains.   
 
Since the in vivo role of CCM3 has yet to be determined, it is difficult to predict the ways 
in which mutant brains will differ from those of controls.  CCM3’s role in vitro has been 
established as being both necessary and sufficient for induction of apoptosis, though, so 
one possibility is that it plays a similar role in vivo.  Were such an occurrence to be true, 
it is hypothesized that mutant brains would be marked by increased cellularity of both 
neurons and astrocytes, the cell types in which Ccm3 has been deleted.  This change 
could potentially result in larger brains in experimental animals, as well as structural 
disorganization given that apoptosis plays a role in cortical organization during 
neurodevelopment.  It is also possible that experimental animals will develop cavernoma-
like lesions since CCM3 mutations in humans cause CCMs, but the likelihood of this 
occurrence remains uncertain given that cavernomas are vascular lesions and that Ccm3 
is selectively inactivated in neural and not endothelial cells in this experimental model.  If 
CCMs are seen in mutant brains, however, this finding would suggest a non-cell 
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autonomous role of CCM3 in neural cells that affects the neurovascular unit and the 
communication occurring between its components, affected neurons and the vasculature.  
Such an occurrence would also potentially implicate disrupted communication within this 
unit as being responsible for lesion formation. 
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METHODS 
Animal Care 
All animals used in this study have been previously described by other groups.  GFAP-
Cre (GFAP) and Emx1-IRES-Cre (Emx1) mice were obtained from Jackson Laboratories.  
Ccm3
lox
 mice were obtained from Dr. Wang Min, Department of Pathology, Yale School 
of Medicine (He et al., submitted).  All mice were maintained in a mixed genetic 
background (C57BL6, 129, FVB).  They were bred by one of the lab’s principle 
investigators, who ensured that all breeding and maintenance occurred in compliance 
with National Institutes of Health guidelines.  The Yale University Institutional Animal 
Care & Use Committee approved the animal protocols used. 
 
Genotyping 
Animals were genotyped within the first two weeks of postnatal development.  This 
responsibility was shared amongst lab members, and as such was completed by students 
and research assistants in the lab, as well as by the principle investigator.  The first step in 
this process was to extract DNA from the animal using a clipping from its tail.  Tails 
were collected in 1.5-milliliter (mL) Eppendorf tubes.  100 microliters (µL) of 50mM 
NaOH was added to each Eppendorf tube, and tubes were then placed at 90 C.  After 30 
minutes, tubes were removed from the heat and immediately placed on ice.  They were 
then centrifuged at 13.2 g for 30 seconds.  30 µL of 1M Tris buffer was then added to 
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each tube, and tubes vortexed briefly.  The resulting DNA suspension was either used 
immediately or stored at 4 C until ready to be used for genotyping. 
 
All genotyping protocols were completed using a set of DNA primers complementary to 
the genomic DNA sequences of interest, which for this study included Cre and Ccm3 lox.  
These sequences were then amplified using a polymerase chain reaction (PCR) protocol 
specific for each set of primers, and gel electrophoresis used for detection of PCR 
products.  Animals containing both Cre and Ccm3
lox/lox
 were considered experimental 
animals.  All other animals were considered as controls, after initial analyses 
demonstrated that Cre
+
;Ccm3
lox/+
 animals were indistinguishable from non-Cre controls.  
 
Weights 
Body weights were measured on a digital scale after anesthetizing animals but prior to 
intracardiac perfusion.  Brain weights were also measured on a digit scale, but 
measurements were made after brains were dissected from the animal’s skull and all 
membranes removed.  Weighs were taken by various lab members, including the author 
of this manuscript. 
 
Electron Microscopy 
Electron microscopy was performed by one of the lab’s principle investigators in order to 
analyze the ultrastructural characteristics of vascular lesions.  Prior to doing so, animals 
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were deeply anesthetized using intracardiac injections of 2.5% glutaraldehyde and 2% 
paraformaldehyde in 0.1M sodium cacodylate buffer (pH 7.4).  Brain tissue was then 
dissected, rinsed, and dehydrated in a series of ethanol dilutions (50-100%) before 
embedding in epoxy resin (Embed 812; Electron Microscopy Sciences).  Tissue was then 
sectioned in the coronal plane at 60 nm on a Reichert ultramicrotome and collected on 
Formvar- and carbon-coated grids.  The samples were stained with 2% uranyl acetate and 
lead citrate and examined on a Philips Tecnai 12 BioTWIN electron microscope (FEI 
Co.).  Images were captured digitally using a CCD camera (Morada; Soft Imaging 
System, Muenster, Germany). 
 
 
In Situ Hybridization 
 
All in situ hybridization was done using riboprobes made by the author of this 
manuscript.  The process for creating riboprobes, as well as the staining protocol used for 
the in situ studies, are described below. 
 
Riboprobe creation 
Gene Cloning:  Primers for each gene of interest were created using the program 
Primer3 and then ordered from commercial sources.  Using these primers and mouse 
cDNA, the gene of interest was amplified using a touchdown PCR protocol.  The 
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resulting PCR products were run on an agarose gel to ensure products were of the 
expected nucleotide length based on the Primer3 results.  Appropriately-sized PCR 
products were then transformed into competent E. coli cells, plated, and plates left to 
grow in an incubator overnight at 37 degrees.  The next day, colonies were selected for 
insert amplification using M13 forward and reverse primers.  Colonies with amplification 
products that matched our expected insert size were then grown overnight in liquid 
culture tubes containing 2 mL of Luria broth (LB) with ampicillin.  The next morning, 
1.5 mL from each of these cultures were transferred to an Eppendorf tube, and the 
remaining 0.5 mL was left at 4 C as a temporary stock solution.  Each Eppendorf tube 
was then centrifuged at 8,000 g for 3 minutes.  The supernatant was then carefully 
removed from each tube so as not to disturb the bacterial pellet.  Next, the DNA from 
each pellet was purified using Quiaquik’s Miniprep protocol (available online at 
http://www1.qiagen.com/literature/handbooks/literature.aspx?id=1000248).  At the end 
of this protocol, the DNA was eluted from the Quiaquik column using 50 uL of Buffer 
EB, and the concentration of the resulting DNA measured using the program NanoDrop.  
Approximately 600 ng of plasmid DNA was then digested in a 10 mL EcoRI digestion 
assay using 0.5 uL EcoRI restriction enzyme and 1 uL of 10X EcoRI buffer.  After a 1.5 
hour incubation at 37 degrees, the assays were run on an agarose gel.  DNA from each 
corresponding lane in the gel that contained DNA fragments of the expected size was 
then sent for sequencing at the W.M. Keck Facility in New Haven, CT.  Once nucleotide 
sequences were returned from the Keck Facility, they were compared to the mouse 
genome using the National Center for Biotechnology Information’s Basic Local 
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Alignment Search Tool.  Sequences with greater than 95% homology to the gene of 
interest were considered to be cloned accurately.   
 
Sequences of accurately cloned genes were entered into NEBcutter V2.0 (New England 
Biolabs, http://tools.neb.com/NEBcutter2/index.php) to determine which restriction 
enzymes would cut the DNA in the desired location in order to linearize it. 
 
 Riboprobe Template Creation: In order to create more DNA for the genes that were 
correctly cloned, new liquid cultures were grown from the temporary stock solution.  The 
Quiaquik Miniprep protocol was once again used to purify DNA from these cultures.  20 
ug of the resulting purified plasmid DNA was then linearized in a 100 uL digestion assay 
using the appropriate restriction enzyme per the results provided by NEBcutter V2.0.   
Resulting products were run on an agarose gel to ensure that linearization was complete.  
Extra proteins were then digested using proteinase K.  A phenol/chloroform extraction 
was then used to extract the riboprobe template.  The template was then precipitated with 
sodium acetate, washed with 70% ethanol (EtOH), and re-suspended in 20 uL DEPC-
H2O for a total concentration of 1 ug/uL.   
 
Riboprobe finalization:  A transcription reaction was then used to create the antisense 
riboprobe from the linearized template.  After the reaction had run for 2 hours at 37 C, 
the probe was precipitated using 100 uL DEPC- H2O, 10 uL of 4 M lithium chloride, and 
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300 uL 100% isopropanol.  This reaction was incubated on ice for 15 minutes, and the 
supernatant decanted.  The pellet was washed with 200 uL 70% EtOH, and centrifuged at 
14,000 rpm at room temperature for 5 minutes.  The supernatant was again decanted and 
the pellet allowed to dry at room temperature before being re-suspended in 100 uL 
DEPC- H2O. 
 
In order to prepare for in situ hybridization, 70 uL of the antisense riboprobe was added 
to an RNase-free mailer containing 14 ml of hybridization solution.  The solution was 
then mixed well and stored at -20 C until ready for use.   
 
Tissue Preparation 
Animals were anesthetized using subcutaneous injections of ketamine (100 mg/kg) and 
xylazine (10 mg/kg).  Once deeply anesthetized, animals were perfused with an 
intracardiac injection of 10 mL of normal saline, followed by 10 mL of 4% 
paraformaldehyde (PFA).  The animal’s brain was then dissected from the skull and post-
fixed for a minimum of 36 hours in a solution of 30% sucrose / 4% PFA before 
sectioning in the coronal plane on a Leica sledge cryomicrotome at 36 µm (Leica 
Microsystems, Germany).  Sections were then mounted on superfrost slides and left to 
dry overnight at room temperature. 
 
Staining Protocol 
24 
 
The following staining protocol was used for all in situ hybridization experiments.  It was 
completed by both the author of this manuscript as well as one of the lab’s principle 
investigators. 
Day One: 
1.  Place slides with mounted sections in RNase-free mailers.  Fix tissue in 4% PFA 
for 15 minutes. 
2. Wash slides in DEPC-PBS 3 times, 5 minutes each wash. 
3. Incubate twice in detergent solution, 15 minutes each time for tissue from animals 
ages 1-20 days, 30 minutes each time for animals older than 20 days. 
4. Wash slides in DEPC-PBS for 10 minutes. 
5. Incubate in proteinase K solution (1ug/ml). 
6. Fix in PFA for 15 minutes. 
7. Wash slides in DEPC-PBS 3 times, 5 minutes each wash. 
8. Place slides in mailer containing desired hybridization solution.  Incubate at 70 C 
overnight. 
 
 
Day Two: 
 
1.  Wash slides three times in Solution X at 70 C for 45 minutes each wash. 
2. Wash slides 3 times in TBST for 15 minutes each time. 
3. Block tissue for 1 hour in 10% lamb serum in TBST. 
4. Incubate tissue in preabsorbed anti-dig antibody diluted to 1:5000 in 1% lamb 
serum in TBST for 2 hours. 
5. Wash three times in TBST, 15 minutes each wash. 
6. Incubate overnight in color solution (made by adding 35 uL NBT and 35 uL BCIP 
per 10 ml NTMT) in the dark, or until color has finished developing.  Color 
development is complete when tissue sections are stained with only a minimal 
amount of background staining.  Staining for corresponding control and 
experimental tissue should continue for equal amounts of time. 
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7. Once the color has finished developing, wash slides in TBST to remove 
background. 
8. Dehydrate slides (see protocol below) before coverslipping in Aquamount and 
allowing to dry overnight. 
 
Sections were analyzed using a Zeiss AxioImager (Zeiss, Oberkochen, Germany) fitted 
with an AxioCam MRc5 digital camera. Images were captured using AxioVision 
software (Zeiss) and assembled in Adobe Photoshop.  
 
 
Immunohistochemistry 
Immunohistochemistry was performed by both one of the lab’s principle investigators as 
well as the author of this manuscript using 3,3'-diaminobenzidine (DAB) staining.  The 
protocols for both tissue preparation and staining are provided below.   
 
Tissue Preparation 
Animals were anesthetized and perfused, and their brains dissected from the skull as 
described previously for in situ hybridization.  Brains were then post-fixed for a 
minimum of 36 hours in a solution of 30% sucrose in PBS before sectioning in the 
coronal plane at 40 µm.   
 
Staining Protocol 
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All steps were performed in scintillation vials on a rocker at room temperature unless 
otherwise noted. 
1.  Wash sections 5 times for 5 minutes each in PBS. 
2. Apply 1% H2O2 for 10 minutes. 
3. Wash sections extensively 4 times for 15 minutes each in PBS. 
4. Apply blocking solution with Triton X-100 for 1 hour 
5. Dilute antibody in blocking solution with Triton X-100.  Keep sections in 
antibody for 2 nights at 4 C. 
6. Wash sections 4 times for 10 minutes each in PBS. 
7. Apply secondary antibody diluted 1:250 in blocking solution without Triton for 2 
hours. 
8. Wash sections 4 times for 10 minutes each. 
9. Prepare ABC mixture (Vector Laboratories) 30 minutes before applying.  Put on 
rocker for 10 minutes, then apply to sections for 2 hours at room temperature.  
10. Wash sections extensively four times for 15 minutes each time 
11. Apply 0.05% DAB, pH 7.4 for 20 minutes in the dark.  Then add 4 uL NH4CL 
(solution: 10% in d H2O), 1 uL glucose oxidase (solution: 8 mg/ml in d H2O), 10 
uL Nickel-ammonium sulfate (solution: 1% in d H2O) and 20 uL 10% glucose.  
Allow solution to develop in darkness, checking level of staining every 5 minutes 
until signal is fully developed. 
12. Wash sections quickly in PBS, then again for 15 minutes, still in darkness. 
13. Mount sections on slides and allow to dry overnight. 
14. Dehydrate slides and coverslip using Aquamount. 
 
Sections were then analyzed, and images captured as described above for in situ 
hybridization. 
 
 
Slide dehydration 
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Prior to coverslipping with Aquamount, all slides were dehydrated by passing through the 
following sequence of solutions for 1 minute each: 
1. Double distilled H2O (ddH2O) 
2. 70% EtOH 
3. 80% EtOH 
4. 90% EtOH 
5. 95% EtOH 
6. 100% EtOH 
7. 100% EtOH 
8. Histoclear 
9. Histoclear 
 
 
Cresyl Violet Staining 
Slides with dried sections were placed in a mailer containing 4% PFA for 15 minutes.  
Next, slides were rinsed with PBS twice, for 5 minutes each time.  Slides were then 
transferred to a slide holder and passed through each of the following solutions for one 
minute sequentially: ddH2O, 70% EtOH, 80% EtOH, 90% EtOH, 95% EtOH, 100% 
EtOH, 100% EtOH, and xylenes.  The slides were then left in a second xylene solution 
for 30 minutes.  After this step, they were transferred back to the first xylene solution, 
followed by 100% EtOH, another 100% EtOH solution, 95% EtOH, 90% EtOh, 80% 
EtOH, 70% EtOH, and ddH2O for one minute each.  The slides were then transferred to 
the staining solution at 42 C for 5 minutes, followed by a 5-minute wash in ddH2O to 
remove excess staining solution.  3 drops of acetic acid were then added to 70% EtOH, 
and the slides were transferred to this solution until good contrast was seen between axon 
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tracts and cell bodies (about 5-10 minutes).  Slides were then dehydrated using the Slide 
Dehydration protocol above before coverslipping with Eukitt. 
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RESULTS 
 
 
Postnatal development 
 
 
GFAP-Cre;Ccm3
lox/lox
 animals 
 
These animals complete embryogenesis and are born in expected Mendelian ratios.  The 
majority of animals fail to thrive following the weaning process, however, and 
approximately 80% die before their fourth postnatal week of life (n > 100).  These 
animals developed an unsteady gait and frequently adopted a circling behavior suggestive 
of vestibular abnormalities.  Experimental animals are noticed to be smaller than their 
control littermates starting around the first week of postnatal life.  By week three they are 
noted to have a body weight that was less than 50% of that of controls.  Their brains, 
however, are larger than those of controls.  This difference in brain weights is first seen 
starting around the second week of postnatal life, when the average brain weight of 
control animals is 0.55 g, and that of experimental animals is 0.48 g.  These differences in 
both brain and body sizes between control and experimental animals persist throughout 
development and into adulthood, where the differences are significant (p<0.01 for brain 
weights of adult control versus experimental animals, as well as for body weights of adult 
control versus experimental animals) using a Student’s t-test (Figure 1, Tables 1 and 2). 
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When sliced coronally, the cortex of experimental brains also appeared to be much 
thicker than those of control animals. 
 
Emx1-Cre;Ccm3
lox/lox
 animals 
 
As with GFAP-Cre;Ccm3
lox/lox
 animals, these animals survive embryogenesis and are 
born in expected Mendelian ratios.  Unlike the GFAP-Cre;Ccm3
lox/lox
 animals, though, 
these animals all survive the weaning process.  Neither gait instability nor circling 
behaviors are noted, likely accounted for by the sparing of cerebellar cells in this 
experimental model.  Although these animals are also noted to have decreased body 
weights and increased brain sizes when compared to control animals across development, 
these findings were not recorded and will not be presented in this work.  Also like GFAP-
Cre;Ccm3
lox/lox
 animals, coronal sections through brains of Emx1-Cre;Ccm3
lox/lox
 animals 
demonstrated a thickened cortex when compared to those of controls. 
 
 
Lesion Detection 
 
Blood-filled vascular lesions resembling human cavernomas were noted in animals of 
both strains upon postmortem brain analyses (Figure 2).  Although most animals with 
lesions had just one lesion, animals were rarely seen that had two, and one animals with 
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even three, lesions.  Among the GFAP-Cre conditional animals, lesions were observed in 
67% (20/30) of animals that were studied.  The earliest lesions to be detected were seen 
during postnatal week three, and all six animals with early lesions seen between three and 
eight weeks of age also had significant hydrocephalus.  Eight Emx1 animals were also 
analyzed for CCMs, with the youngest of these animals being nine months of age and the 
oldest being 16 months.  Lesions were seen in over 80% of these animals.  All lesions 
detected were in brain structures expressing either the GFAP or Emx1 promoter, and 
therefore in regions subject to CCM deletion.  For GFAP animals, these regions included 
the cerebral cortex, olfactory bulb, midbrain, pons, medulla and cerebellum.  Affected 
areas in Emx1 animals included the cerebral cortex and olfactory bulb. 
 
 
Lesion Analysis 
Lesions were examined using antibody staining as well as electron microscopy to 
determine their composition and to compare it to that of human cavernomas.  An 
antibody directed towards PECAM, a marker of endothelial cells, was applied to brain 
sections containing lesions.  After staining, resulting lesions appeared to consist of 
multiple dilated channels outlined by a single layer of stained cells, suggesting a single 
endothelial cell layer comprising the sinusoids of lesions (Figure 3A).  In situ 
hybridization for Igf2, a marker of mesenchymal cells, was also done on cavernoma-
containing brain sections.  Sections failed to demonstrate staining in the region of the 
lesion, but did show staining around the lesions, as well as throughout the remainder of 
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brain sections, suggesting the CCMs to be devoid of intervening parenchyma (Figure 
3B).   
 
Next, electron microscopy was used to determine ultrastructural characteristics of the 
lesions.  This technique again identified a single layer of endothelial cells forming the 
vascular channels that comprise lesions.  These cells are surrounded by a generally intact 
but irregular basement membrane, with collagen supporting the other side of this 
membrane.  Tight junctions are seen separating endothelial cells.  Erythrocytes and 
platelets are seen within the lumens of lesions, and erythrocytes are additionally seen 
abluminally (Figure 4). 
 
 
Cytoarchitecture 
 
Nissl staining was used to evaluate the cytoarchitecture of animals’ brains.  This protocol 
stains rough endoplasmic reticulum, allowing for detection of cell bodies.  Two main 
differences were seen when comparing the Nissl staining results of control and 
experimental animal brains.  The first of these differences was noticed in the cerebral 
cortex.  Unlike control animals, which have clearly defined cortical layers, the cerebral 
cortex of experimental animals was disorganized and lacking structure.  No discrete 
cortical layers could be distinguished.   
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The other main difference between the brains of these two groups of animals was seen in 
the hippocampal formation.  While this structure in control animals consisted of a 
discrete line of tightly packed cells, in experimental animals this strict organization was 
lacking.  Cells in the hippocampal formation of experimental animals were loosely 
arranged, giving this structure an appearance as if was blurred since it lacked the sharp 
discrete contours seen in controls.  This observation held true for both GFAP and Emx1 
strains of experimental animals (Figures 5 and 6). 
 
Finally, an observation made only in brains of the GFAP animals was the disorganization 
of the cerebellum.  Compared to the cerebellum of control animals, that of GFAP animals 
lacked a tight cellular alignment and clear definition along the folia of the cerebellum 
(Figure 7).  This difference is not seen in the cerebellum of Emx1 mutant animals 
because this brain region is not targeted by the Emx1 promoter. 
 
 
GFAP/vimentin Staining 
 
Both GFAP and vimentin stain intermediate filaments in astrocytes, with GFAP being 
expressed generally in astrocytes and vimentin being expressed in a cytoskeletal element 
seen only in activated (reactive) astrocytes.  Staining for both of these markers using in 
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situ hybridization was used to compare the presence of astrocytes in adult control animal 
brains to that of adult experimental animal brains.  GFAP staining in control animals was 
darkest in structures containing mostly white matter, and otherwise it was distributed 
relatively evenly throughout the brain in sparse amounts.  Vimentin, on the other hand, 
was rarely detected in the brains of control animals, with noticeable staining located only 
in ependymal cells.  For GFAP and Emx1 experimental brains, though, staining for both 
GFAP and vimentin was significantly increased compared to controls.  The majority of 
this increased GFAP staining in mutant brains occurred in areas subject to Ccm3 deletion.  
For the GFAP strain of animals these regions included the cerebellar and cerebral cortices 
as well as subcortical structures such as the basal ganglia and hippocampus.  In the Emx1 
strain, increased levels of staining were limited to the cerebral cortex and hippocampal 
formation (Figure 8).  For vimentin, the majority of the increased staining in both the 
GFAP and Emx1 experimental animals was located in the cortex and hippocampal 
formation (Figure 9). 
 
In addition to these widespread increases in astrocyte staining throughout affected brain 
areas of mutant animals, local staining increases in GFAP were also seen surrounding 
lesions.  Areas of heavy staining were noted in the immediate vicinity of cavernomas, 
fully circumscribing the lesions and extending into the surrounding tissue (Figure 10). 
 
 
Connexin43 Staining 
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Connexin43 is a protein found in gap junctions connecting the foot processes of 
astrocytes comprising the BBB.  As such it plays an important role in cell signaling 
across this barrier [12].  In situ hybridization was used to detect the presence of 
connexin43 in both control and experimental animal brains, and resulting staining 
patterns of the different brains were compared (Figure 11).  Overall staining for 
connexin43 was decreased in experimental animals when compared to controls in both 
GFAP as well as in Emx1 strains.  Affected areas again appear to be limited to regions 
and structures in which Ccm3 was deleted.  Not only were these results seen globally 
throughout the brain as an overall decrease in staining density, but they were also seen 
locally in the area immediately surrounding lesions.  These regions immediately adjacent 
to cavernomas were completely devoid of connexin43 staining. 
 
 
Aquaporin 4 Staining 
Aquaporin 4 is a water channel seen in astrocytic foot processes in direct contact with 
capillaries of the BBB.  In situ hybridization was used to detect the presence of 
Aquaporin 4 RNA in control and experimental mice brains, and these results compared 
among the different animal types (Figure 12).  In control brains, Aquaporin 4 staining 
was seen throughout most brain structures, especially in the hippocampal formation and 
midbrain.  Regions in which staining was heaviest seemed to parallel areas of heaviest 
connexin43 staining, consisting with findings of another group that have looked at 
mRNA staining of both of these molecules [58].  In experimental animals, Aquaporin 4 
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staining took on a similar pattern in terms of the structures in which it was expressed, but 
the overall amount of staining appeared to be less.  These results were true for both 
GFAP and Emx1 animal strains.  
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DISCUSSION 
Ccm3 neural conditional knock-out mice survive embryogenesis and develop lesions 
resembling human CCMs, providing an animal model through which the 
pathophysiology of this devastating disease can be studied.  In this particular study, the 
brains of these mice were examined and compared to those of control animals to 
determine differences that exist between the two.  Although few animals in which Ccm3 
was deleted from GFAP-expressing cells and their progeny survived into adulthood, mice 
lacking Ccm3 from Emx1-expressing cells and their progeny almost always survived, 
with the oldest mouse currently being over 16 months of age.   
 
Aside from these differences in lifespan, which are likely attributable to the deletion of 
Ccm3 from cerebellar cells of the GFAP animals given the behavioral phenotype seen in 
these mice, few differences were noted between the GFAP and Emx1 animal strains.  
Morphologically both strains were noted to have relatively large brains and small body 
sizes when compared to control animals, and both strains also developed lesions 
resembling human cavernomas in brain regions where Ccm3 had been deleted.  The Nissl 
and in situ hybridization staining patterns were also similar for both strains, with the only 
difference in staining between the two animal lines relating to the different brain regions 
targeted by these two different promoters.  Unlike the Emx1 promoter, which is 
expressed specifically in cells of the neocortex and hippocampus, the GFAP promoter is 
also expressed in cells of the cerebellum and other subcortical structures, causing changes 
to be seen in these locations as well as those areas seen in Emx1 animals.   It therefore 
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seems likely that Ccm3 is playing a similar role in both of these animals, and further 
characterizing this role is possible by comparing the differences between these 
experimental animals and normal controls. 
 
The first major differences observed between control and experimental animals were 
morphological, relating to differences in the brain and body sizes seen in control and 
experimental animals.  The weights of these animals’ brains and bodies were used to 
quantify these differences.  Although the sample size is small, the graphs of the brain 
weight data show a clear difference between control and experimental animals’ brains 
beginning in the second week of postnatal development, with experimental brains 
weighing more than those of controls.  This difference continues into adulthood, where, 
with larger sample sizes allowing for calculation of statistical significance, a significant 
difference is appreciated.  At the same time, results show that the body weights of 
experimental animals are less than those of controls beginning very early in postnatal life, 
and again this trend persists into adulthood, where it is statistically significant.  
Considering these two trends together shows that the increased brain weight is an 
absolute increase rather than one that is relative to body size.  In fact, given that the body 
weights of experimental animals is decreased compared to those of controls further shows 
that the increased brain weight is an absolute and not a relative increase because the 
weights of both of these variables are moving in opposite directions.  The relative 
increase in brain size in these animals is therefore even greater, making this increase in 
weight even more substantial. 
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Although size changes in many regions are likely responsible for the overall weight 
increase in experimental brains, further comparison of control and experimental brains 
that have been sectioned in the coronal plane consistently reveal gross differences 
between particular structures.  The most obvious of these regions is the cerebral cortex, 
which appears to be much thicker in experimental brains.  Another area in which gross 
differences are noted between experimental and control brain sizes is in the ventricular 
system, where experimental animals are noted to have a much larger ventricles than those 
of controls, especially with respect to the lateral ventricles, which are extremely dilated in 
experimental animals.  While these observations can easily be made thanks to the 
relatively large size of these structures even in control animals, other size differences are 
likely to be present that could not be noted on a gross level.  Further comparisons 
between control and experimental brains made on a smaller scale would likely yield even 
more differences.   
 
One of the main goals of this study was to provide further insight into what is accounting 
for these phenotypic changes in the brains of experimental mice.  Since in vitro studies 
have shown that Ccm3 is both necessary and sufficient for induction of apoptosis [53], 
one hypothesis to explain these findings is that this size increase is secondary to an 
increased number of cells.  Since apoptosis is not occurring as it normally would, more 
cells are surviving and therefore increasing the size and mass of the animals’ brains. 
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Other techniques were also used to further test this hypothesis.  Analysis of brain 
cytoarchitecture using Nissl staining was one such method.  Staining patterns in the 
cerebral cortex were of particular interest since coronal sections through mutant brains 
demonstrate a dramatic size increase in this structure when compared to controls. When 
viewing the staining results, however, it was difficult to compare the cell number or 
staining intensity between the experimental and control brains because of the vastly 
different organization of these structures in the two groups.  The cerebral cortex of 
control brains consisted of well-defined cortical layers, while experimental brains lacked 
this rigid layout.  There were no defined cortical layers in mutant brains, and cells in this 
region of experimental brains also seemed to be arranged less densely than cells in the 
control cortex.  Therefore, despite not being able to comment on differences in absolute 
cell numbers between the cortexes of control and experimental brains, these staining 
patterns still provide insight on differences between the brains of these different animals.  
More specifically, these observations suggest that the absence of Ccm3 somehow causes 
the large, disordered cortex seen in experimental brains. One potential explanation for 
these cortical changes is a decrease in apoptosis in brains of experimental animals.  Prior 
research has shown that apoptosis is an important determinant in both the size of the CNS 
during development as well as the appropriate size and shape of the forebrain in 
mammals [59, 60].  CCM3 has already been shown to have an apoptotic role in vitro.  
Overexpression of CCM3 in endothelial cells lines has been shown to induce apoptosis in 
vitro, and siRNA inhibition of CCM3 in endothelial cells results in lower levels of cell 
death [53].  Furthermore, astrocytes isolated from GFAP-Cre;Ccm3
lox/lox
 animals are 
resistant to cycloheximide-induced apoptosis [61], and these mutant astrocytes also show 
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increased proliferation (A. Louvi, L. Chen, A. Two, H. Zhang, W. Min, and M. Günel: 
Loss of CCM3 function in neuroglia leads to cerebral cavernous malformations, 
submitted).  Therefore, if CCM3 also has a role in inducing apoptosis in vivo, it could be 
responsible for the cortical changes seen in experimental mice.   
 
To further investigate the hypothesis that CCM3 has a role in apoptosis in vivo, in situ 
hybridization was used to look for staining differences between control and experimental 
brains that might indicate increases in cellularity.  The first in situ experiments done were 
for GFAP and vimentin, both markers of astrocytes.  These results showed mRNA for 
both of these markers to be globally upregulated in mutant brain structures in which 
Ccm3 had been deleted when compared to control brains, suggesting an increase in 
astrocytes in these regions of experimental brains.  Since vimentin is specifically 
upregulated in reactive astrocytes, these results also suggest the presence of reactive 
gliosis in experimental brains.  In addition to providing a possible explanation for why 
mutant brains are larger than those of controls, the reactive gliosis also provides some 
insight into the molecular changes that may be occurring in these animals’ brains.  
Reactive gliosis is the brain’s normal physiologic response to any type of insult, 
including infection, degeneration, ischemia, and exposure to toxins.  It occurs when, 
following one of these types of injury, astrocytes at the site of the insult hypertrophy and 
sometimes even proliferate to form a scar-like structure that limits the extent of the 
injury’s spread.  The reactive astrocytosis seen in experimental brains therefore suggests 
some form of injury in these animals’ brains.  Given that these animals develop vascular 
lesions, ischemia seems like a probable source of the insult.  Further comparison of the 
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vasculature of control and experimental animals supports this possibility.  First, brains of 
experimental animals have a decreased density of blood vessels.  In addition, vessels in 
experimental brains appear to be disorganized and to have an increased diameter when 
compared to vessels in control brains (Louvi et al., submitted).  These findings support 
ischemia’s role as a potential mechanism for reactive gliosis since it seems unlikely that 
these disordered vessels could adequately support the neurons and increased astrocytes of 
the larger experimental brains.  Ischemia is therefore another possible mechanism of the 
reactive gliosis that occurs in these brains.   
 
These differences in the vasculature of experimental brains as well as the probable 
presence of ischemia in these animals again highlight the presence of vascular deficits 
seen in these Ccm3 conditional knock-out animals.  In this animal model, however, Ccm3 
is only knocked-out from neurons and astrocytes, indicating that there must be some 
connection between the cells targeted by the knock-out and those comprising the 
vasculature.  Given that astrocytes and endothelial cells communicate with each other by 
signaling across the BBB, the neurovascular unit is implicated as a potential source of 
dysfunction in experimental animals.    
 
To further investigate this concept that impairment at the level of the neurovascular unit 
is responsible for the changes in the brains of experimental animals, in situ hybridization 
was done to detect the mRNA of connexin43, a protein in gap junctions of the BBB, and 
aquaporin4, a water channel also found in the BBB.  Compared to that seen in control 
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brains, the staining intensity of both connexin43 and aquaporin4 mRNA was greatly 
diminished in experimental brains, suggesting a decrease in these BBB gap junctions and 
water channels respectively.  This result is even more significant when taking into 
account the previously discussed finding that experimental brains have an increase in 
activated astrocytes compared to controls.  With more of these astrocytes, one would 
expect more of both connexin43-containing gap junctions and aquaporin 4 water 
channels to be necessary in experimental brains in order to fulfill their respective roles, 
which involve maintaining integrity and signaling between different components of the 
BBB.  Without the correct number and distribution of these channels, the integrity of 
individual neurovascular units, including communication across them, may be 
compromised.  Over time, these deficits could potentially lead to ischemia, which would 
then be accompanied by the reactive gliosis seen in experimental animals. 
 
In situ hybridization results must be interpreted with caution, though.  The findings 
presented are all qualitative rather than quantitative, and therefore care must be made 
when drawing conclusions from these results.  To help minimize discrepancies between 
staining intensities for control and experimental brains, all tissue was handled in the same 
fashion.  Both control and experimental brain sections for each given marker were 
developed for the same amount of time so that they were exposed equally to the probe.  
Furthermore, when viewing and imaging the stained sections, the light source was kept 
constant so as not to affect the brightness of the resulting images.  Nonetheless, the 
current findings could be confirmed using Western blot to analyze the protein content of 
the proteins of interest in control and experimental brains. 
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Assuming that this hypothesis of disorganization at the level of the neurovascular unit is 
correct, several questions remain to be answered.  The first of these questions is what 
causes CCMs to develop.  One possible explanation for lesion formation relates to neural 
injury.  This hypothesis is supported by the focal nature of lesions, as well as their age 
dependence.   The youngest animals in which lesions were seen were three weeks old.  In 
all of these young animals with lesions, hydrocephalus was also present.  No lesions were 
found in animals this young without hydrocephalus, but lesions were routinely seen in 
animals without hydrocephalus that were over a few months old.  These findings suggest 
the possibility that an underlying injury such as stress caused by hydrocephalus was seen 
in these animals, and given the existing mutation in these animals’ brains, the addition of 
this insult caused the development of a CCM.  This theory can be tested by selectively 
injuring the brains of mutant animals at a young age such as by sacrificing one of the 
main arteries to the brain and later examining these brains for the presence of 
cavernomas.  If this injury theory is true, these animals will develop cavernomas within a 
short period of time following the vascular insult, and multiple lesions may even be seen 
depending on the severity of the ischemia. 
 
This theory of a focal insult being necessary for lesion development also helps answer 
another question regarding experimental animals, which is why more lesions are not seen 
per animal.  Since the reactive astrocytosis and changes in the neurovascular unit in 
experimental animals are widespread and seen throughout areas of the brain affected by 
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the Ccm3 deletion, it is unclear why more lesions are not seen per animal.  Although a 
few animals had multiple lesions, the majority only had one lesion.  With such global 
changes in the brain, one would expect many more lesions to develop in experimental 
brains.  If both a focal insult and the widespread vascular changes seen in experimental 
animals are necessary for lesion development, CCM formation would not only be less 
common among experimental animals, but it would also be more likely to occur as 
animals aged, which is exactly what was observed among animals studied.  
 
Like any animal model, though, these Ccm3 conditional knock-out mice are not without 
their limitations.  Widespread changes such as the reactive gliosis seen throughout 
experimental brains are not recognized as being a part of the disease phenotype in 
humans.  This difference could potentially be accounted for by differences in Ccm3 
expression between humans and mice, but current studies of CCM3 expression suggest it 
is similar in mice and humans [52].  Another possible explanation for the different 
phenotypes seen in the human disease and the experimental model is related to the two-
hit hypothesis of the disease pathogenesis in humans.  According to this model, humans 
with the inherited form of the disease have a germline mutation in one of their two CCM3 
alleles, leaving one functioning copy of the allele.  Focal lesions develop when a second 
sporadic hit, or mutation, affects the remaining intact CCM3 allele, completely 
inactivating CCM3 in these specific cells only.  In the mouse model, however, both 
copies of the Ccm3 allele are knocked-out, completely inactivating this gene in all cells 
targeted by the promoter.  These targeted cells in these animals therefore lack the one 
functioning copy of CCM3 seen in most cells of human patients, perhaps explaining the 
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more widespread neural pathophysiology seen in the experimental model.  Nonetheless, 
given that these animals develop lesions that resemble human cavernomas after 
knocking-out one of the genes implicated in cavernoma development in humans, this 
animal model still seems appropriate for studying lesion development and the role of 
Ccm3 in the pathophysiology of this disease, potentially allowing for results from this 
model to be generalized to humans, and thus potentially implicating dysfunction at the 
neurovascular unit as also contributing to disease pathophysiology in humans. 
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FIGURES 
 
 
 
 
Figure 1:  Graphs of average body (A) and brain (B) weights of control and experimental 
animals at various postnatal days, as well as body (C) and brain (D) weights of adult 
animals.  Brain weights of experimental animals are noticeably greater than those of 
controls starting around the second week of postnatal life, a trend that continues into 
adulthood.  Body weights of experimental animals are observed to be smaller than those 
of controls beginning early in development and this trend also continues into adulthood. 
55 
 
  
 
 
Figure 2:  Images of lesions seen in the medulla (A and B) and in the dorsal midbrain (C 
and D) of GFAP mice.  (B) and (D) are magnified images of the lesions seen in (A) and 
(C) respectively.  Scale bars in (A) and (C) represent 1 mm, and those in (B) and (D) are 
200 µm. 
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Figure 3:  Lesion analysis using PECAM (A) and Igf2 (B) staining.  PECAM staining of 
the lesion shows channels in the lesion lined by a single layer of endothelial cells.  A 
higher magnification of the boxed region is shown just to the right of the main image.  
Igf2 staining shows mesenchymal cells surrounding but not within the lesion. 
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Figure 4:  Lesion analysis using electron microscopy.  In image (A), electron microscopy 
confirms the single layer of endothelial cells (e) comprising lesions, with tight junctions 
(arrows) joining these cells.  An irregular basement membrane (BM) supported by 
connective tissue (c) is seen in the area surrounding lesions.  In (B) and (C), erythrocytes 
(er) and platelets (t) are seen in the lumen of lesions (L), and erythrocytes are additionally 
seen abluminally.  An axon (a) is also seen adjacent to the lesion in (B).  Scale bars 
represent 500 nm in (A), 5 µm in (B), and 1 µm in (C).  
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Figure 5:  Nissl staining of representative control (A, C, E, and G) and GFAP 
experimental (B, D, F, H) brain sections.  (A) and (C) are from a postnatal day seven 
control animal, while (B) and (D) correspond to approximately the same brain regions 
seen in (A) and (C) respectively, but in a postnatal day 13 experimental animal.  (E) and 
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(F) are magnifications of (C) and (D) respectively.  Asterisks mark the cortex, which is 
divided into discrete layers in control brains that are not seen in experimental brains.  
Arrows point to the hippocampal formation for each animal.  Cells of the hippocampal 
formation are tightly packed into a discrete layer in control brains, while those of the 
experimental brains are loosely arranged and disorganized. 
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Figure 6:  Nissl staining of representative control (A, C and E) and Emx1 experimental 
(B, D, and F) brain sections.  (A) and (B) are taken at approximately equivalent levels of 
the brain of postnatal day 15 animals, while (C) and (D) respectively are magnifications 
of these sections to further highlight the cortical and hippocampal differences between 
the two.  (E) and (F) are both from five month old animals.  Asterisks mark the cortex, 
which is divided into discrete layers in control brains that are not seen in experimental 
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brains.  Arrows point to the hippocampal formation for each animal.  Cells of the 
hippocampal formation are tightly packed into a discrete layer in control brains, while 
those of the experimental brains are loosely arranged and disorganized. 
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Figure 7:  Nissl staining of the cerebellum of a representative postnatal day nine control 
(A) and postnatal day seven GFAP experimental (B) brain.  Cells in the control brain 
appear to be arranged more closely and seem to form more well-defined layers. 
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Figure 8:  GFAP staining in control (A, C, and E) and GFAP (B and D) and Emx1 (F) 
experimental brains.  (A) and (B) are from seven month old animals, and (C-F) from 10 
month old animals.  Staining in experimental brains is much more intense than that seen 
in control brains. 
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Figure 9:  Vimentin staining in control (A, C, and E) and GFAP (B and D) and Emx1 (F) 
experimental brains.  (A) and (B) are from nine month old animals, (C) and (D) from 10 
month old animals, and (E) and (F) from five month old animals.  Staining in 
experimental brains is much more intense than that seen in control brains. 
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Figure 10:  GFAP staining in two different five month old GFAP experimental brains 
containing lesions.  Staining is darkest in regions immediately surrounding lesions. 
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Figure 11:  Connexin43 staining in postnatal day seven control (A) and Emx1 
experimental (B) brains, as well as in five month old control (C) and Emx1 experimental 
(D) brains.  Staining (blue) in control brains is darker than that of experimental brains. 
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Figure 12:  Aquaporin 4 staining in five month old control (A) and Emx1 experimental 
(B) brains.  Staining (blue) in control brain is much more intense than that seen in the 
experimental brain. 
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TABLES 
 
Postnatal 
Day  
 
Control Animals  Experimental Animals  
Average 
Weight (g)  
Number of 
Animals  
Average 
Weight (g)  
Number of 
Animals  
1  0.17  5  0.16  2  
2  0.15  8  0.15  3  
6  0.29  5  0.29  3  
7  --  --  0.36  2  
13  0.49  1  --  --  
15  0.46  1  0.55  1  
18  0.40  1  0.49  1  
20  0.44  3  0.47  2  
21  0.48  13  0.52  5  
22  0.46  4  0.50  4  
26  0.49  1  0.53  1  
 
Table 1:  Brain weights of non-adult control and GFAP experimental animals examined 
in this study, arranged by postnatal day. 
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Postnatal 
Day  
 
Control Animals  Experimental Animals  
Average 
Weight (g)  
Number of 
Animals  
Average 
Weight (g)  
Number of 
Animals  
1  2.02  17  1.88  4  
2  1.94  8  1.57  3  
3  --  --  1.13  2  
6  4.74  8  3.06  4  
7  4.40  15  4.23  6  
8  6.60  4  4.86  10  
9  6.56  8  2.1  1  
11  7.75  6  6.4  2  
13  6.40  2  3.16  2  
14  8.18  5  5.98  4  
15  8.52  6  7.70  4  
16  9.55  2  9.88  2  
17  8.70  3  5.87  3  
18  11.49  1  5.64  2  
20  7.20  3  6.15  2  
21  12.33  14  5.43  6  
22  11.03  7  6.00  6  
25  12.50  1  --  --  
26  --  --  10.95  2  
Table 2:  Body weights of non-adult control and GFAP experimental animals examined 
in this study, arranged by postnatal day. 
